➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Moodys
Dow
Merck
Medtronic

Last Updated: June 14, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Fotemustine


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Fotemustine?

Fotemustine is an investigational drug.

There have been 17 clinical trials for Fotemustine. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2012.

The most common disease conditions in clinical trials are Melanoma, Uveal Neoplasms, and Lymphoma. The leading clinical trial sponsors are Bristol-Myers Squibb, Mingzhi Zhang, and Hoffmann-La Roche.

There is one US patent protecting this investigational drug and twenty-four international patents.

Recent Clinical Trials for Fotemustine
TitleSponsorPhase
A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System LymphomaMingzhi ZhangPhase 4
Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System LymphomaMingzhi ZhangPhase 4
A Phase I/IIa Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMTGenenta SciencePhase 1/Phase 2

See all Fotemustine clinical trials

Clinical Trial Summary for Fotemustine

Top disease conditions for Fotemustine
Top clinical trial sponsors for Fotemustine

See all Fotemustine clinical trials

US Patents for Fotemustine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Fotemustine   Get Started Free Heat shock protein 70 (hsp-70) receptor ligands Duke University (Durham, NC)   Get Started Free
Fotemustine   Get Started Free Compounds and their methods of use Agios Pharmaceuticals, Inc. (Cambridge, MA)   Get Started Free
Fotemustine   Get Started Free Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus Seattle Genetics, Inc. (Bothell, WA)   Get Started Free
Fotemustine   Get Started Free Anti-FGFR3 antibodies and methods using same Genentech, Inc. (South San Francisco, CA)   Get Started Free
Fotemustine   Get Started Free Bispecific antigen-binding constructs targeting HER2 Zymeworks Inc. (Vancouver, CA)   Get Started Free
Fotemustine   Get Started Free Method of diagnosing and treating cancer using B-catenin splice variants The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Fotemustine

Drugname Country Document Number Estimated Expiration Related US Patent
Fotemustine World Intellectual Property Organization (WIPO) WO2015148714 2034-03-25   Get Started Free
Fotemustine Australia AU2015231053 2034-03-21   Get Started Free
Fotemustine Brazil BR112016021620 2034-03-21   Get Started Free
Fotemustine Canada CA2943339 2034-03-21   Get Started Free
Fotemustine China CN106231900 2034-03-21   Get Started Free
Fotemustine Eurasian Patent Organization EA201691896 2034-03-21   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Medtronic
Baxter
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.